Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

SELL
$63.71 - $70.74 $30,453 - $33,813
-478 Reduced 8.76%
4,977 $318,000
Q1 2023

May 08, 2023

SELL
$65.71 - $74.53 $38,506 - $43,674
-586 Reduced 9.7%
5,455 $378,000
Q4 2022

Feb 07, 2023

SELL
$68.48 - $81.09 $21,982 - $26,029
-321 Reduced 5.05%
6,041 $434,000
Q1 2022

May 04, 2022

SELL
$61.48 - $73.72 $2,151 - $2,580
-35 Reduced 0.55%
6,362 $465,000
Q4 2021

Feb 08, 2022

SELL
$53.63 - $62.52 $14,533 - $16,942
-271 Reduced 4.06%
6,397 $399,000
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $20,709 - $24,258
-350 Reduced 4.99%
6,668 $395,000
Q2 2021

Aug 06, 2021

SELL
$61.91 - $67.42 $38,569 - $42,002
-623 Reduced 8.15%
7,018 $469,000
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $215,023 - $243,661
3,724 Added 95.07%
7,641 $474,000
Q3 2020

Nov 09, 2020

SELL
$57.43 - $63.64 $89,246 - $98,896
-1,554 Reduced 28.4%
3,917 $236,000
Q2 2020

Aug 06, 2020

SELL
$54.82 - $64.09 $151,741 - $177,401
-2,768 Reduced 33.6%
5,471 $322,000
Q1 2020

May 07, 2020

SELL
$46.4 - $67.43 $837,334 - $1.22 Million
-18,046 Reduced 68.66%
8,239 $459,000
Q4 2019

Feb 10, 2020

BUY
$49.21 - $64.19 $989,170 - $1.29 Million
20,101 Added 325.05%
26,285 $1.69 Million
Q3 2019

Nov 06, 2019

BUY
$42.77 - $50.71 $264,489 - $313,590
6,184 New
6,184 $314,000
Q2 2018

Aug 01, 2018

SELL
$50.53 - $62.98 $230,113 - $286,810
-4,554 Closed
0 $0
Q1 2018

May 09, 2018

BUY
$59.92 - $68.98 $8,988 - $10,347
150 Added 3.41%
4,554 $288,000
Q4 2017

Feb 01, 2018

BUY
$59.94 - $65.35 $13,186 - $14,376
220 Added 5.26%
4,404 $270,000
Q3 2017

Nov 02, 2017

BUY
$55.23 - $63.74 $231,082 - $266,688
4,184
4,184 $267,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Trillium Asset Management, LLC Portfolio

Follow Trillium Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trillium Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Trillium Asset Management, LLC with notifications on news.